Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
The drug will be available in 600 hospitals and 105 DTPs
They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights
It is developing the drug candidate to potentially treat immunological diseases
Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
Subscribe To Our Newsletter & Stay Updated
